GaryAllanUlanerMD, PhD, FACNM

Nuclear Medicine

James & Pamela Muzzy Endowed Chair of Molecular Imaging and Therapy, Hoag Family Cancer Institute. Professor of Radiology and Translational Genomics, University of Southern California

Join to view full profile

Dr. Ulaner is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Ulaner's full profile

Already have an account?

Office
16105 Sand Canyon
Suite 215
Irvine, CA 92618
Phone+1 949-557-0285

Education & Training

University of Southern California/Los Angeles General Medical Center (USC/LA General)Residency, Radiology-Diagnostic, 2004 - 2009
University of Southern California/Los Angeles General Medical Center (USC/LA General)Residency, Nuclear Medicine, 2004 - 2005
Johns Hopkins University School of MedicineInternship, Transitional Year, 2000 - 2001
Stanford University School of MedicineClass of 2000

Certifications & Licensure

CA State Medical License 2020 - 2026
NJ State Medical License 2013 - 2021
NY State Medical License 2009 - 2021
American Board of Nuclear Medicine Nuclear Medicine
American Board of Radiology Diagnostic Radiology

Clinical Trials

FACBC PET and PEM as a Staging Tool and Indicator of Therapeutic Response in Breast Cancer Patients Start of enrollment: 2013 May 01
Completed
Early Phase 1
Fluorestradiol (FES) PET/CT for Imaging Estrogen Receptor Status Start of enrollment: 2013 Aug 01
Completed
Early Phase 1
Can HER2 Targeted PET/CT Imaging Identify Unsuspected HER2 Positive Breast Cancer Metastases, Which Are Amenable to HER2 Targeted Therapy? Start of enrollment: 2014 Nov 06
Completed
Not Applicable
Imaging With a New Agent That Finds a Cancer Protein Called HER2 Start of enrollment: 2017 Mar 31
Completed
Phase 1
First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody Start of enrollment: 2018 Sep 05
Completed
Phase 1, Phase 2
18F-fluoroestradiol (FES) PET/CT for Breast Cancer Start of enrollment: 2021 Jan 15
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

Role of [F]FDG PET/CT in patients with invasive breast carcinoma of no special type: Literature review and comparison between guidelines.
David Groheux, Sofia C Vaz, Philip Poortmans, Ritse M Mann, Gary A Ulaner
Breast. 2024-12-01
2 citations
Prospective investigation of amino acid transport and PSMA-targeted positron emission tomography for metastatic lobular breast carcinoma.
Aliza Mushtaq, Ismaheel O Lawal, Saima Muzahir, Sarah C Friend, Manali Bhave
European Journal of Nuclear Medicine and Molecular Imaging. 2024-11-01
4 citations
F-Labeled Fluoroestradiol PET/CT: Current Status, Gaps in Knowledge, and Controversies-Expert Panel Narrative Review.
Matthew F Covington, Sophia R O'Brien, Courtney Lawhn-Heath, Austin R Pantel, Gary A Ulaner
AJR. American Journal of Roentgenology. 2024-10-01

Journal Articles

Efficacy of MEK Inhibition in Patients with Histiocytic Neoplasms
Robert J Young, Mario Lacouture, Neal Rosen, David M Hyman, Raajit Rampal, Gary A Ulaner, Benjamin H Durham, Lynn A Brody, Nature

Press Mentions

NUCLIDIUM Announces First Patient Imaged in Phase 1 Study Evaluating 61Cu-Based Radiotracer in Patients with PSMA-Positive Prostate CancerOctober 21st, 2024
Hoag Hospital Opens Its Remodeled $28 Million Cancer CenterFebruary 22nd, 2023
New Molecular Targeted Therapy for Metastatic Prostate Cancer Wins FDA Approval at Hoag Family Cancer InstituteApril 4th, 2022
Join now to see all